Partial Improvement in Negative Schizophrenic Symptoms After Amphetamine

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1982 Jan 1

PMID 6817367

Citations 15

Authors

B Angrist

E Peselow

M Rubinstein

J Corwin

J Rotrosen

Affiliations

Soon will be listed here.

Abstract

In stable schizophrenic outpatients with predominantly "defect state" symptomatology amphetamine caused a reduction in negative symptoms that was statistically significant but not complete (i.e. these symptoms remained clinically discernible). The possibility that dopaminergic hypofunction contributes some elements to the schizophrenic defect state is presented, along with some limited data compatible with this concept. These findings are compared to prior studies in recently hospitalized schizophrenic subjects, and discussed with respect to recent theoretical concepts regarding the role of dopamine in schizophrenic psychopathology.

Citing Articles

Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models.

Partyka A, Golebiowska J, Marciniec K, Canale V, Trybala W, Satala G Pharmacol Rep. 2025; .

PMID: 40064751 DOI: 10.1007/s43440-025-00713-w.

Adjunctive methylphenidate extended release in patients with schizophrenia: Protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes.

Zhand N, Attwood D, Labelle A, Joober R, Robertson C, Harvey P Contemp Clin Trials Commun. 2024; 41:101337.

PMID: 39205914 PMC: 11350445. DOI: 10.1016/j.conctc.2024.101337.

The early identification of psychosis: can lessons be learnt from cardiac stress testing?.

Gupta S, Ranganathan M, DSouza D Psychopharmacology (Berl). 2015; 233(1):19-37.

PMID: 26566609 PMC: 4703558. DOI: 10.1007/s00213-015-4143-3.

Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.

Lasser R, Dirks B, Nasrallah H, Kirsch C, Gao J, Pucci M Neuropsychopharmacology. 2013; 38(11):2140-9.

PMID: 23756608 PMC: 3773663. DOI: 10.1038/npp.2013.111.

How have developments in molecular imaging techniques furthered schizophrenia research?.

Thompson J, Urban N, Abi-Dargham A Imaging Med. 2011; 1(2):135-153.

PMID: 21243081 PMC: 3020795. DOI: 10.2217/IIM.09.22.

References

KORNETSKY C . Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Arch Gen Psychiatry. 1976; 33(12):1425-8. DOI: 10.1001/archpsyc.1976.01770120029002. View

Crow T . Molecular pathology of schizophrenia: more than one disease process?. Br Med J. 1980; 280(6207):66-8. PMC: 1600263. DOI: 10.1136/bmj.280.6207.66. View

Angrist B, Rotrosen J, Gershon S . Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology (Berl). 1980; 72(1):17-9. DOI: 10.1007/BF00433802. View

Janowsky D, Davis J, Sekerke H . Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry. 1973; 28(2):185-91. DOI: 10.1001/archpsyc.1973.01750320023004. View

BOWERS Jr M . Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry. 1974; 31(1):50-4. DOI: 10.1001/archpsyc.1974.01760130034005. View

Angrist B, Sathananthan G, Gershon S . Behavioral effects of L-dopa in schizophrenic patients. Psychopharmacologia. 1973; 31(1):1-12. DOI: 10.1007/BF00429294. View

Ogura C, Kishimoto A, Nakao T . Clinical effect of L-dopa on schizophrenia. Curr Ther Res Clin Exp. 1976; 20(3):308-18. View

Gerlach J, Luhdorf K . The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo. Psychopharmacologia. 1975; 44(1):105-10. DOI: 10.1007/BF00421193. View

Post R, Fink E, Carpenter Jr W, Goodwin F . Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry. 1975; 32(8):1063-9. DOI: 10.1001/archpsyc.1975.01760260127011. View

10.

INANAGA K, Inoue K, Tachibana H, Oshima M, Kotorii T . Effect of L-dopa in schizophrenia. Folia Psychiatr Neurol Jpn. 1972; 26(2):145-57. DOI: 10.1111/j.1440-1819.1972.tb01119.x. View

11.

Angrist B, Rotrosen J, Gershon S . Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology (Berl). 1980; 67(1):31-8. DOI: 10.1007/BF00427592. View

12.

HOPE J, CALLAWAY E, SANDS S . Intravenous pervitin and the psychopathology of schizophrenia. Dis Nerv Syst. 1951; 12(3):67-72. View